-+ 0.00%
-+ 0.00%
-+ 0.00%

MiNK Therapeutics Q3 EPS $(0.65) Misses $(0.61) Estimate

Benzinga·11/14/2025 13:23:17
Listen to the news
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.61) by 5.69 percent. This is a 41.3 percent decrease over losses of $(0.46) per share from the same period last year.